Cytogen 2026 Q1 Results: Revenue Growth, Loss Reduction, Debt Ratio Improvement

Consolidated revenue of 6.38 billion KRW (up 14% YoY), operating loss of 1.47 billion KRW (improved from 2.35 billion loss), net loss of 1.27 billion KRW (improved from 2.43 billion loss)
Debt ratio improved to 67.22% (from 72.92% at year-end), cash and equivalents of 24.48 billion KRW
Subsidiary Genomcare recorded revenue of 2.94 billion KRW and net profit of 0.77 billion KRW in the genomic analysis segment
Convertible bonds: 5th series 155 billion KRW (conversion price 9,167 won) and 6th series 98 billion KRW (10,690 won) outstanding; partial redemption of 3.3 billion KRW of 6th series reduced derivative liabilities
Ongoing lawsuit related to US subsidiary ExperTox (claim of 1.3 million USD, insurance coverage up to 2 million USD)
R&D expenses of 0.81 billion KRW (12.85% of revenue)
Changed from co-CEO system to sole CEO Ahn Ji-hoon in February 2026
Major shareholders: CandyX Holdings 30.79%, Byung-hee Jeon 8.75%